A molecular model of plasmic degradation of crosslinked fibrin
- PMID: 6460319
- DOI: 10.1055/s-2007-1005040
A molecular model of plasmic degradation of crosslinked fibrin
Abstract
Based on structural studies of both degrading insoluble crosslinked fibrin and of soluble derivatives, we have developed a model to explain the principal structural and physical features of plasmic degradation for crosslinked fibrin in vitro from the completely intact matrix to terminally degraded soluble derivatives. Plasmic digestion is viewed as a continuous process of proteolytic attack on accessible, enzyme-susceptible sites; but the process is separated into four phases based on solubility characteristics of the degrading fibrin matrix and on the structures of the soluble derivatives. The critical event of solubilization occurs only as the result of coincident cleavages at complementary sites in the basic two-stranded half-staggered overlap fibrin structure, resulting in the release of two-stranded complexes held together by noncovalent forces. The four smallest complexes which are released into solution have structures corresponding to DD/E, DY/YD, YY/DXD, and YXD/DXY. The protein initially solubilized has a constant composition with a predominance of large derivatives which are composed of at least on fragment from each of the two strands of the protofibril. Following their release into solution the larger complexes are converted in vitro to smaller ones by the continued action of plasmin, so that the complex found following prolonged digestion is DD/E. It is proposed that this newly defined group of complexes [11] represents the major form of circulating plasmic derivatives of crosslinked fibrin.
Similar articles
-
Plasmin degradation of cross-linked fibrin.Ann N Y Acad Sci. 1983 Jun 27;408:397-406. doi: 10.1111/j.1749-6632.1983.tb23260.x. Ann N Y Acad Sci. 1983. PMID: 6223558
-
Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.J Clin Invest. 1980 Nov;66(5):1033-43. doi: 10.1172/JCI109931. J Clin Invest. 1980. PMID: 6448866 Free PMC article.
-
Degradation of cross-linked fibrin by human leukocyte proteases.J Lab Clin Med. 1986 Apr;107(4):342-52. J Lab Clin Med. 1986. PMID: 3514776
-
Fibrin degradation products. A review of structures found in vitro and in vivo.Ann N Y Acad Sci. 2001;936:594-610. Ann N Y Acad Sci. 2001. PMID: 11460518 Review.
-
Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.J Oslo City Hosp. 1977 Jun;27(6):69-80. J Oslo City Hosp. 1977. PMID: 142131 Review. No abstract available.
Cited by
-
Interaction of amorphous calcium phosphate with fibrin in vitro causes decreased fibrinolysis and altered protease profiles: implications for atherosclerotic disease.Inflammation. 2001 Oct;25(5):319-29. doi: 10.1023/a:1012831900153. Inflammation. 2001. PMID: 11820459
-
Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.Nanomedicine (Lond). 2012 Jul;7(7):1017-28. doi: 10.2217/nnm.11.179. Epub 2012 Feb 21. Nanomedicine (Lond). 2012. PMID: 22348271 Free PMC article.
-
Comparison of an immunochemical assay for plasma fibrinogen and a turbidimetric thrombin clotting technique to discriminate hyperlipidaemic patients from healthy controls.J Clin Pathol. 1990 Jun;43(6):508-10. doi: 10.1136/jcp.43.6.508. J Clin Pathol. 1990. PMID: 2116454 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources